[go: up one dir, main page]

MX2016001694A - Formulacion de vacuna de sacarido. - Google Patents

Formulacion de vacuna de sacarido.

Info

Publication number
MX2016001694A
MX2016001694A MX2016001694A MX2016001694A MX2016001694A MX 2016001694 A MX2016001694 A MX 2016001694A MX 2016001694 A MX2016001694 A MX 2016001694A MX 2016001694 A MX2016001694 A MX 2016001694A MX 2016001694 A MX2016001694 A MX 2016001694A
Authority
MX
Mexico
Prior art keywords
vaccine formulation
saccharide vaccine
saccharide
formulation
manufacture
Prior art date
Application number
MX2016001694A
Other languages
English (en)
Inventor
Krikor Torossian
Erin Weston
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2016001694A publication Critical patent/MX2016001694A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001169Tumor associated carbohydrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Se proporcionan composiciones de vacuna sustancialmente estables, así como métodos para su uso y elaboración.
MX2016001694A 2013-08-08 2014-08-01 Formulacion de vacuna de sacarido. MX2016001694A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1314248.4A GB201314248D0 (en) 2013-08-08 2013-08-08 Saccharide vaccine formulation
US201361865166P 2013-08-13 2013-08-13
PCT/EP2014/066591 WO2015018753A1 (en) 2013-08-08 2014-08-01 Saccharide vaccine formulation

Publications (1)

Publication Number Publication Date
MX2016001694A true MX2016001694A (es) 2016-05-02

Family

ID=49261915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001694A MX2016001694A (es) 2013-08-08 2014-08-01 Formulacion de vacuna de sacarido.

Country Status (15)

Country Link
US (1) US20170119864A1 (es)
EP (1) EP3030258A1 (es)
JP (1) JP2016527291A (es)
KR (1) KR20160040705A (es)
CN (1) CN105592857A (es)
AR (1) AR097188A1 (es)
AU (1) AU2014304668A1 (es)
BE (1) BE1022254B1 (es)
BR (1) BR112016002349A2 (es)
CA (1) CA2920221A1 (es)
GB (1) GB201314248D0 (es)
IL (1) IL243873A0 (es)
MX (1) MX2016001694A (es)
SG (1) SG11201600786RA (es)
WO (1) WO2015018753A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2119451A4 (en) * 2007-03-09 2012-05-16 Otsuka Pharma Co Ltd LYOPHILIZED PREPARATION COMPRISING THE INFLUENZA VACCINE AND PREPARATION METHOD THEREOF

Also Published As

Publication number Publication date
GB201314248D0 (en) 2013-09-25
BE1022254B1 (fr) 2016-03-04
KR20160040705A (ko) 2016-04-14
WO2015018753A1 (en) 2015-02-12
SG11201600786RA (en) 2016-03-30
CA2920221A1 (en) 2015-02-12
US20170119864A1 (en) 2017-05-04
IL243873A0 (en) 2016-04-21
BR112016002349A2 (pt) 2017-08-01
CN105592857A (zh) 2016-05-18
JP2016527291A (ja) 2016-09-08
AR097188A1 (es) 2016-02-24
EP3030258A1 (en) 2016-06-15
AU2014304668A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
IL267997A (en) Preparations, formulations and methods for treating eye diseases
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2020005181A (es) Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
IL243752B (en) Multispecific antibodies, preparations containing them and their uses
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EP3089754A4 (en) Single vial vaccine formulations
PH12018500071B1 (en) Plinabulin compositions
MX2020004205A (es) Composiciones antibioticas de ceftolozano.
PL2981600T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń i ich wytwarzanie
EP3065729A4 (en) Novel formulations
MX2015008588A (es) Composiciones y metodos para la transfeccion de polinucleótidos.
SG11201507608PA (en) Toxoid, compositions and related methods
SG10201900598TA (en) Factor viii formulation
WO2014146111A3 (en) Analgesic compounds and methods of use
MX368268B (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
MX2015016603A (es) Composiciones de corticosteroides.
SG11201507462QA (en) Compositions and methods for live, attenuated alphavirus formulations
MX2014015199A (es) Formulacion de pexiganan estable.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
SG11201507578PA (en) Toxoid, compositions and related methods
EP3074049A4 (en) Novel cell-penetrating compositions and methods using same
EP3057972A4 (en) Novel compositions, uses and methods for their preparation